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Abstract 
Brief periods of ischemia are known to confer to the myocardium an increased resistance to 
the injury due to a later and more prolonged ischemic episode. This phenomenon, known as 
ischemic pre-conditioning (IPC), is ensured by different biological mechanisms. Although an 
exhaustive comprehension of them has not been reached yet, it is widely accepted that 
mitochondria are pivotally involved in controlling cell life and death, and thus in IPC. Among 
the several signaling pathways involved, as triggers and/or end-effectors, in the mitochondrial 
mechanisms of cardioprotection, an important role is played by the activation of potassium 
channels located in the mitochondrial inner membrane (mitoK) of cardiomyocytes. Presently, 
different types of mitoK channels have been recognized in the heart, such as ATP-sensitive 
(mitoKATP) and calcium-activated (mitoBKCa and mitoSKCa) potassium channels. 
Consistently, drugs modulating mitochondrial KCs, on one hand, have been employed as 
useful experimental tools for early basic studies on IPC. On the other hand, activators of 
mitochondrial KCs are promising and innovative therapeutic agents for limiting the 
myocardial injury due to ischemic episodes.  
In this review, we report the experimental evidence supporting the role of mitoK channels in 
signaling pathways in the mechanisms of cardioprotection and an overview on the most 
important molecules acting as modulators of these channels, with their profiles of selectivity. 
Some innovative pharmaceutical strategies for mitochondriotropic drugs have been also 
reported. Finally, an appendix describing the main experimental approaches usually employed 
to study mitoK channels in isolated mitochondria or in intact cells, has been added. 
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1- ISCHEMIA/REPERFUSION INJURY 
 
Acute myocardial ischemia is one of the major causes of morbidity in western society and 
despite the recent advances in therapy, it remains a major cause of mortality. Indeed, the 
reduced coronary blood supply leads to cell death and loss of cardiomyocytes population, 
resulting in serious and often irreversible consequences on myocardial functionality [1]. The 
myocardial cell death during an ischemic episode is caused by necrosis, mostly due to the 
irreversible opening of the mitochondrial permeability transition pore (MPTP) and by the 
stimulation of the death receptor-induced necrosis, a process known as necroptosis [2-3]. 
Currently, the most effective strategy to reduce ischemic damage is an early reperfusion, but 
paradoxically the reperfusion in itself is responsible for an additional damage. Indeed, the 
global myocardial damage is referred to as ischemia-reperfusion (I/R) injury [4]. 
 
A Ischemia-induced cell death 
During ischemia, the rate of glycolysis in the myocardial cell rises, in order to produce energy 
by mitochondrion-independent pathways; this causes a metabolic rise of lactic acid and 
acidification of the intracellular pH. Besides, the Na+/K+ ATPase is inhibited, because of the 
decline of ATP concentration and the intracellular [Na+] increase, then the Na+/H+ antiporter 
is inhibited, with further lowering of the pH. The Na+/Ca++ antiporter, that usually pumps 
Ca++ out of the cell and Na+ into the cell, is inhibited or reversed, leading to an overload of 
Ca++, responsible for hypercontracture, that contributes to the irreversible opening of MPTP 
[5] ATP is rapidly converted to ADP and AMP, which leak out of the cell and contribute to 
reduced cardiac performance. During the ischemia episode, the cytosol concentration of ROS 
exhibits a biphasic behaviour: in the first minutes, a small amount of ROS is produced; while 
after 20-25 minutes, a dramatically higher ROS concentration is formed. The depletion of 
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ATP, together with  elevated intracellular [Ca++] and ROS, leads the cell to a gradual and 
irreversible decline of its integrity [5-7] (Figure 1A).  
 
B Reperfusion-induced cell death 
The beginning of the reperfusion is associated with a burst of ROS production, primarily 
formed by complex 1, 2 and complex 3 of the respiratory chain, but also by other 
mitochondrial oxidative enzymes, such as xanthine oxidase, NAPH oxidase, monoamine 
oxidase and aconitase [8-10]. The mitochondrial proteins are particularly susceptible to ROS-
induced damage: ROS have direct effects on the respiration and play a critical role in the 
opening of the MPTP [5-7, 11, 12]. MPTP is a high conductance mega-channel, anchored 
between the mitochondrial outer and inner membrane. When it is assembled, it allows the 
connection between the cytoplasm and mitochondrial matrix [13]. It is formed by an 
arrangement of the voltage-dependent anion channel (VDAC), located in the outer 
mitochondrial membrane, with the adenine nucleotide transporter (ANT) and the proteic 
translocator (TSPO) , located in the inner mitochondrial membrane, and cyclophilin D in the 
matrix [14-16]. 
It is thought that during ischemia the MPTP is closed, since the pore is powerfully inhibited 
by low pH (<7) [17]. Indeed the rapid energization of mitochondria at reperfusion leads to 
electrogenic uptake of Ca++, previously accumulated into the cytosol during ischemia, that 
supports a “destructive” hypercontracture. This factor, together with the rise of ROS 
production and the recovery of neutral pH, promotes the opening of MPTP [18-20]. The 
opening of just a single pore in one mitochondrion is sufficient to cause its immediate 
depolarization [21], and then enlisting further MPTP opening, since the MPTP activation is 
triggered by depolarization. As a consequence of MPTP opening, all small molecular weight 
solutes (< 1.4 kDa) equilibrate across the inner membrane; in contrast, the largest molecules 
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(i.e. proteins) remain entrapped in the matrix, exerting an osmotic pressure that leads to the 
uptake of water and matrix swelling [22, 23]. Although the unfolding of the cristae allows the 
matrix to expand without rupture of the inter-membrane, the outer one breaks and leads to the 
release of pro-apoptotic proteins, confined in the inter-membrane space, such as cytochrome c 
[24-26]. There is an increasing evidence that the time of MPTP opening is closely correlated 
with the extent of damage. Indeed inhibitors of the pore opening (such as cyclosporine A) 
protect the heart from injury and many preconditioning strategies, aim at inhibiting opening of 
MPTP [27-30] (Figure 1B). 
 
2- MECHANISMS OF CARDIOPROTECTION 
A Ischemic pre-conditioning (IPreC) 
Transient brief episodes of I/R (typically of 2-5 minutes)confer on myocardium an increased 
resistance against a subsequent prolonged severe episode of I/R. This phenomenon is known 
as ischemic pre-conditioning (IPreC) and is recognized as one of the most powerful 
endogenous cardioprotective mechanisms. IPreC was first described in dog hearts [31], and 
thereafter confirmed in many mammalian species, including humans [32-35].  
In particular, two distinct phases of IPreC are recognized: an early one, the “classic IPreC”, 
that lasts for 3 h after the stimulus, and a delayed one, the “second window of IPreC”, starting 
about 24 h after the triggering stimulus and lasting for up to 3 days following the stimulus 
[32, 36-38]. 
Early IPreC is due to the involvement of already existing biomolecules acting as effectors; 
whereas the delayed one is mediated by newly synthesized cardioprotective proteins [39] 
(Figure 2). 
 
B Ischemic post-conditioning (IPostC) 
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More recently, Zhao and colleagues demonstrated that brief intermittent cycles of coronary re-
occlusion (typically 30 seconds) and reperfusion (30 seconds) during the first minute of 
reperfusion after a severe ischemic event, reduce the infarct size by about 40% in canine 
hearts [40]. As observed for the IPreC, also the IPostC has been confirmed in many other 
mammalian species [41-42]. Presently, the mechanisms involved in IPostC have not been 
fully understood, but reduction of ROS production, mitochondrial Ca++ overload and 
inflammation have been observed [35,40, 43] (Figure 2). 
 
C Remote ischemic pre- and post-conditioning (ReIPreC, ReIPostC) 
Schmidt et al. demonstrated that brief intermittent cycles of limb ischemia afforded a 
significant protection during myocardial infarction, preserving the cardiac function and 
reducing the arrhythmias typical of reperfusion [44]. Similarly, Li et al. also observed that 
limb brief ischemia periods reduced the myocardial damage after an ischemic period by 
inhibiting oxidative stress [45]. Again, renal ischemia episodes, in the first minute of 
reperfusion, reduced the myocardial infarct size in rats [46]. 
These phenomena are called remote ischemic preconditioning (ReIPreC) and remote ischemic 
postconditioning (ReIPostC). They consist in brief episodes of I/R applied to an organ distant 
from the heart, before or after prolonged ischemia, and afford cardioprotection [46-48]. 
Although the molecular mechanisms accounting for ReIPreC and ReIPost are not well 
understood (most studies are largely observational), these phenomena have been clearly 
observed in many mammalian species, including rat, rabbit and pigs, and are likely to require 
the transfer of protective factors or signals through humoral and/or neural pathways, such as 
some kinases [49].  
D Pharmacological pre-conditioning (Ph-PreC) 
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A clinical procedure of IPreC, anticipating a myocardial infarct, is almost impossible to be 
applied, since  the infarct onset cannot be predicted. In contrast,  a clinical cardioprotective 
strategy based on  IPostC is conceptually feasible in patients with acute myocardial infarct, 
but it shows many difficulties, risks and disadvantages [47, 50]. The definition of the 
signaling pathways of IPreC and IPostC, paves the way to develop pharmacologic strategies, 
to mimic the protection with drugs able to trigger the same mitochondrial pathways (Figure 
2). The IPreC, as well as IPostC which recruits analogous signaling pathways, is mediated by 
numerous endogenous factors, including adenosine [51], acetylcholine [52], bradykinin [53] 
and opioids [54-59] and gaseous molecules, such as NO [60-63] and H2S [64].  
Moreover, the IPreC and IPostC involve the activation of protein kinase C (PKC), isozymes 
which sometimes exert opposing roles in both normal signaling and disease states [65], and 
possibly other kinases, such as reperfusion injury salvage kinase (RISK), glycogen synthase 
kinase 3 beta (GSK3B), signaling transducer and activator of transcription 3 (STAT3) [63].  
As regard the isoforms of PKC, the ε and  isoforms play opposite roles in cardioprotection. 
In particular, PKCε activation is cardioprotective, while PKCδ activation mediates the most 
part of the injury induced by myocardial ischemia [66]. Recent evidence shows that PKCε 
activates the mitochondrial aldehyde dehydrogenase 2 (ALDH2), which removes products of 
lipid peroxidation [67] thus protecting the mitochondrial functions. Moreover, Baines et al. 
reported that the translocation of PKC can be considered as an additional mechanism for 
protection: the direct phosphorylation of the MPTP components inhibits the pore opening [38, 
68, 69]. In contrast, PKCδ inhibition during the reperfusion phase is cardioprotective. 
Actually, the PKC activation  triggers the mitochondrial pyruvate dehydrogenase kinase 
[70], thus inhibiting both pyruvate dehydrogenase and ATP regeneration. Moreover, PKC 
activation induces impaired perfusion  of myocytes after the ischemic event, thus leading to 
further tissue injury [71]. However, the role of PKC for cardioprotection in mammalian is still 
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controversial. Heusch et al. reported that the PKC inhibitor staurosporine did not prevent 
IPreC in swine [72]. Moreover, after the first encouraging evidence of Mochly-Rosen that 
inhibition of PKCδ at the onset of reperfusion reduced the tissue injury, the clinical trial failed 
to show any significant benefit [73]. 
In addition to PKC isozymes, other different protein kinases have been proposed as mediators 
of cardioprotective pathway. For example, STAT3 has been recently identified in 
mitochondria and its expression is correlated with the reduction of myocardial injury by IPreC 
and IPostC. consistently, the deletion of STAT3 or its inhibition abrogated the 
cardioprotection mediated by conditioning strategies [74, 75]. 
Again, several types of potassium channels, present in the inner mitochondrial membranes 
and similar to those present in the plasma membrane of several cell types, have been 
suggested to be triggers and end-effectors in cardioprotection. Presently, ATP-sensitive [76] 
and calcium-activated [77-80] potassium channels have been recognized and has been proved 
to be involved in the regulation of mitochondrial volume, membrane potential, pH-regulation 
and apoptosis. 
On the other hand, connexin 43, a transmembrane protein which allow direct communication 
between cytoplasm of adjacent cells, by the formation of gap junctions, has been described in 
mitochondria and demonstrated to participate in the IPreC [81]. Interestingly, mitochondrial 
connexin 43 contributes to mitochondrial potassium uptake, forming hemichannel-like 
structures or modulating existing ion transporters [81-83]. Noteworthy, connexin 43 is 
hypothesized to be involved in the cardioprotection induced by the KATP activator diazoxide, 
because, in connexin 43 deficient mice, diazoxide is devoid of beneficial effects [84]. 
 
3- MITOCHONDRIAL POTASSIUM CHANNELS INVOLVED IN 
CARDIOPROTECTION 
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The critical role of mitochondria and the involvement of mitochondrial pathways activated by 
IPreC or IPostC are crucial in the mechanism of cardioprotection. In this context, the 
mitochondrial potassium channels (mitoK) represent an attractive pharmacological target.  In 
normal conditions, the mitochondrial inner membrane is almost impermeable to K+. Hence, 
when mitoK channels are closed, the entry of K+ ions is negligible and easily buffered by a 
K+/H+ antiporter, that pumps K+ out of the matrix; therefore the influence of such a K+ 
leakage on the mitochondrial membrane potential is almost negligible, although it can 
regulate the matrix volume.  
By contrast, in stress or ischemia conditions, the opening of mitoK channels causes a 
significant influx of K+ ions, with diffusion of water and uptake of anions, resulting in matrix 
swelling. This effect ensures the preservation of low permeability of the outer membrane for 
nucleotides and then the creation of a favorable gradient for ATP synthesis and transfer to 
cytoplasm [85]. Then, the activation of mitoK channels controls the matrix volume, 
preserving a narrow intermembrane space, necessary to preserve an effective oxidative 
phosphorylation. Moreover, the opening of mitoK channels produces a mild depolarization of 
membrane potential, responsible for a reduced uptake of Ca++ into the mitochondrial matrix, 
preserving it from the Ca++-overload and the subsequent MPTP opening [86]. 
Finally, the cardioprotection offered by mitoK channel activation can be also linked to a mild 
uncoupling of mitochondrial respiration [87] (Figure 3). 
Effects of mitoK channel activators is summarized in table 1. 
 
A MitoKATP channels  
The first mitoK channel recognized as an effective target for Ph-PreC was the ATP-sensitive 
one (mitoKATP).  KATP-openers, such as bimakalim and cromakalim, were reported to produce 
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cardioprotective effects at doses devoid of any influence on action potential duration, 
suggesting the existence of an intracellular site of action, independent of the sarcolemmal 
channels [88-91]. 
Later, the first direct evidence about a role of mitoKATP channels was  the observation of the 
effect of the KATP opener diazoxide on bovine heart mitochondria, at a concentration clearly 
lower than that necessary for opening the sarcolemmal channel [92]. Although for several 
years there has been a debate on which type of KATP channel (sarcolemmal or mitochondrial) 
was involved in cardioprotection, presently, it is generally accepted that the mitochondria play 
a crucial role in the I/R event and the role of the mitoKATP channel is likely to be prevalent 
[93]. 
Indeed, numerous experimental reports in support of this hypothesis have been collected in 
the last years, demonstrating that the IPreC, and most recently even the IPostC, can be 
mimicked by several selective mitoKATP channel activators [94-98]. 
To date, no definitive molecular identity has been assigned to the mitoKATP channel; 
nevertheless, a resemblance with the sarcolemmal one has been proposed. In fact, mitoKATP is 
likely to be an hetero-octameric complex, containing KIR6.1 or KIR6.2 subunits and SUR2 
sulphonylurea receptor subunits, while the SUR1 subunit seems to be excluded (for a more 
complete and authoritative examination of the molecular composition of mitoKATP channels: 
[99-102]). Recently, a mitochondrial-specific SUR2 variant (mitoSUR2), generated by an 
intraexonic splicing of the classical SUR2 subunit, has been described; noteworthy, in SUR2 
knock-out mice, in which the mitoSUR2 form remained expressed, the IPreC strategy was 
still effective in reducing ischemic injury [103].  
Moreover, the pharmacological cross-talk between the mitoKATP channel and mitochondrial 
respiratory complex II (succinate dehydrogenase) led to the hypothesis that complex II could 
be a further component of the mitochondrial channel [104]. Interestingly, a step forward in 
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understanding the molecular structure of the mitoKATP channel was achieved by the O’Rourke 
group: they demonstrated that the ROMK (renal outer medullary potassium) channel, 
normally expressed on the surface membrane in the kidney cells, is localized on the inner 
membrane of cardiac mitochondria and mediates ATP-sensitive K+ flux, giving protection 
against cell death stimuli. This observation led to speculation that mitoROMK may be a pore-
forming subunit of the mitoKATP channel [105].  
 
B MitoKATP activators 
The first pioneering experiments probing the cardioprotective properties of KATP channel 
activators were carried out with cromakalim or its analogs. It is a benzopyran compound 
completely devoid of selectivity for the mitoKATP channels, thus the protective effects are 
endowed with vasodilatation and action potential duration shortening, due to the activation of 
the sarcolemmal KATP channels present in vascular smooth muscle cells and cardiomyocytes, 
respectively. The benzopyran nucleus represents the scaffold most widely subjected to 
chemical manipulation in order to develop novel mitoKATP activators [106].  
Diazoxide, a prototype of the benzothiadiazine class, has been reported to open mitoKATP 
channels with a good, but not absolute, selectivity. At moderate doses it can activate mitoKATP 
channels, producing Ph-PreC, without showing non-selective effects. Nevertheless, at higher 
doses, an activation of sarcolemmal KATP channels cannot be excluded [107-108]. Although 
the role of ROS in the IPreC is controversial, Heusch and colleagues demonstrated that 
diazoxide conferred protection through the generation of free radicals [84, 109]. MitoKATP-
independent mechanisms of diazoxide have also been hypothesized and a possible target is 
likely to be the mitochondrial succinate dehydrogenase [110-112]. Indeed, Wojkovich and his 
colleagues proved that the complex II is an important regulator or component of the mitoKATP 
channel, since diazoxide is able to activate the channel, but also to inhibit the complex II; 
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conversely, a complex II inhibitor atpenin A5, is able to open at lower concentration the 
mitoKATP channel [113-114].  
Unfortunatly, diazoxide is also responsible for undesired vasodilator and hyperglicaemic 
effects [95, 115-116]. 
Attempting to ameliorate the selectivity versus the mitoKATP channel, the Bristol Mayer 
Squibb Company has developed original hybrids, conjugating the benzopyran moiety of 
cromakalim with the cyanoguanidine nucleus (another important scaffold of non-selective 
KATP openers, such as pinacidil) [106, 117]. 
This research led to two interesting compounds: BMS 180448, endowed with a good 
cardioprotective potency, but still conserving a poor vasorelaxing potency and BMS191095, a 
4-N aryl-substituted benzopyran, were synthesized. The latter molecule resulted about  30-
fold more selective than BMS 180448 and its pharmacological effect was antagonized by 5-
hydroxy decanoic acid (5-HD), a selective mitoKATP blocker. Nevertheless, BMS 191095 is 
not suitable for clinical use, because of its neuronal toxicity; it remains only a useful tool for 
research purposes [118]. Afterwards, Lee and his colleagues developed new molecules based 
on a benzopyran scaffold bearing a 2’-carboxyalkyl-indole or 2’-carboxyalkyl-indoline 
nucleus in 4-position. In particular two 2-ethyl-esters showed the best cardioprotective 
activity in vivo and in vitro, and a weak vasorelaxing potency. The cardioprotective effect of 
these novel compounds was completely blocked by 5-HD, suggesting the involvement of the 
mitoKATP channels [119]. Moreover, the benzopyranyl-indole analog KR-31466 reduces 
hypoxic injury in heart-derived H9c2 cells through mitoKATP opening. Jung et al. suggested 
that this protection from hypoxia-induced death could also involve PKC activation [120].  
More recently, a novel series of spiro-morpholine and spiro-morpholone benzopyran 
derivatives has been projected and synthetized by us [95, 121-123]. The insertion of spiro-
cyclic substitution on the carbon 4 of the benzopyran group had the objective to confer a 
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structural rigidity in this molecular portion, in order to improve the selectivity vs the mitoKATP 
channel.  
Some compounds of this series exhibited a good cardioprotective profile in ex vivo models of 
I/R and modest effects on vascular smooth muscle. In particular, the best of the series, the N-
acetyl spiro-morpholone derivative (F163) has been submitted to further studies. The 
resolution of the racemic mixture, according to the results previously obtained with BMS 
180448, showed the enantioselectivity of the cardioprotective profile; in fact only the 
levorotatory enantiomer was effective [124]. An in depth pharmacological investigation 
confirmed the cardioprotection on cardiomyoblasts culture submitted to anoxia/reperfusion 
and in vivo on acute myocardial infarct; moreover the mitochondrial target of F163 has been 
demonstrated [95]. Actually, it was observed that the novel compound was able to produce all 
the typical effects of a mitoK channel activation: mild depolarization, reduction of Ca++-
uptake, increase of Ca++-release and mild mitochondrial swelling, reversed by selective 
mitoKATP blockers. According to the literature, a close correlation between drug-induced 
depolarization and Ca++-release from the matrix of Ca++-preloaded mitochondria was also 
reported, leading to the observation that a small depolarization is sufficient to greatly affect 
the movement of Ca++. This study suggested that the novel derivative could represent an 
interesting prototype for the development of innovative mitoKATP openers, that are more 
potent than diazoxide and devoid of significant influences on blood pressure and glucose 
metabolism [95] (in figure 4 are shown the chemical structures of KATP activators).  
Presently, no specific study attempted to identify the binding site of KATP activators on the 
mitoKATP channels; however, in analogy with the sarcolemmal channels, the interaction with 
the SUR subunit seems to be more probable hypothesis. 
 
C Mitochondrial calcium-sensitive potassium channels 
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C.1 MitoBKCa channels and their activators 
In 2002, O’Rourke’s laboratory for the first time found the presence of a large conductance 
calcium-activated potassium channel (BKCa, or KCa1.1) on the guinea-pig cardiac inner 
membrane of mitochondria (mitoBKCa) [79], previously described only on mitochondria of 
glioma cells without assigning a specific function [77]. In this work, they employed patch-
clamp mitoplasts and identified the K+ current across this channel as a component of 
background K+ conductance. Moreover, they identified a role for the mitoBKCa channel in the 
protection against ischemic injury. Indeed, the BKCa activator, NS1619, decreased the infarct 
size following an I/R period, and this effect was antagonized by the BKCa blocker paxilline 
[79, 104]. Other reports have also confirmed that the pharmacological opening of mitoBKCa 
channels mimicked both early and delayed preconditioning [125-127], as well as 
postconditioning [94].  
Noteworthy, cardiopreventive effects of NS1619 seemed to be also mediated by an anti-
inflammatory activity that prevented leukocyte-endotelial cells adhesion and preserved 
mitochondrial functionality [128-130]. 
However, micromolar concentrations of NS1619 cause also anomalous effects on 
mitochondria, such as decreased respiratory control, insensitivity to selective BKCa blockers, 
and a deep membrane potential drop even in the absence of K+ [131-132]. Such a profile of 
NS1619, similar to diazoxide, is due to off-target effects on mitochondria, including 
inhibition of the respiratory chain and uncoupling [133]. Notably, at higher concentrations 
NS1619 can also inhibit L-type Ca++-channels, calcium-activated Cl- currents, voltage-gated 
calcium channels and K+ and Na+ channels; these aspecific effects complicate the 
interpretation of the role of mitoBKCa channels in cardioprotection [134-137].  
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Another novel BKCa activator, chemically unrelated to, but more potent and specific than 
NS1619, is NS11021 [138]. It exerts protective effects through activation of BKCa channels; 
these effects were completely inhibited by paxilline. Nanomolar concentrations of NS11021 
improved the bioenergetic performance of heart mitochondria, through enhanced K+-uptake 
and mild swelling, without large changes in mitochondrial membrane potential (ΔΨ). 
Interestingly, the improvement of mitochondrial respiration observed with NS11021 by Aon 
et al. was due to a decrease in state 4 respiration (related to the phase in which all of the ADP 
is converted to ATP), while the state 3 respiration (corresponding to the phase in which ADP 
is converting to ATP) was unchanged. Such an unexplained behavior of NS11021 is different 
from mitoKATP openers, which dose-dependently improve respiration through an increase of 
state 3 [139-140].  
Besides the most extensively studied NS-series, the more potent compound CGS7184 (ethyl 
1-[(4-chlorophenyl)-amino]oxo]-2-hydroxy-6-trifluoromethyl-1H-indole-3-carboxylate) has 
been developed [141]. CGS7184 reduced the ROS production in mitochondria isolated from 
rat brain [142], and depolarized the ΔΨ in the EAhy926 endothelial cell line [143]. These 
effects, that could be predictive of protective properties, seem to be related to modulation of 
intracellular Ca++ homeostasis, probably by interaction with the sarcoplasmic reticulum [144]. 
The molecular composition of mitoBKCa channels is yet unknown; although an auxiliary 
beta1 subunit, necessary for the IPreC and identical to the sarcolemmal one, was found [145-
146]; however some splice variants at the mitochondrial level cannot be excluded. Presently, 
it is thought that the mitochondrial and sarcolemmal structures are conserved, and then the 
mitoBKCa is likely to be composed of four alpha subunits, forming the pore, and four 
auxiliary beta-subunits, which modulate calcium sensitivity and activity [147].  
Very recently, the Toro group unequivocally demonstrated the existence of the KCNMA1 
(Slo1) gene at the mitochondrial level, encoding for BKCa channel. Their hypothesis was 
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supported with experiments on Kcnma1 knockout mice, in which NS1619 failed to produce 
cardioprotection [148]. 
Notably, the combined application of sub-maximally effective concentrations of two different 
mitoK activators NS1619 and diazoxide on cardiac mitochondria, produced additive effects, 
reducing flavoprotein oxidation and ouabain-induced mitochondrial Ca++ overload; thus 
contributing to cardioprotection [149] (in figure 4 are shown the chemical structures of BKCa 
activators).  
 
C.2 MitoIKCa channels 
Besides the mitoBKCa channels, an intermediate conductance calcium-sensitive potassium 
channel (IKCa, or KCa3.1) has been detected in purified mitochondria of human colon 
carcinoma cells [99, 150], of HeLa cells and embryonic fibroblasts [151]. Its molecular 
weight is the same of IKCa channel localized on plasma membrane, suggesting equivalent 
biophysical and pharmacological properties [151]. The physiological role of mitoIKCa has not 
been studied in detail so far, but TRAM-34 (an IKCa inhibitor) induced hyperpolarization of 
the mitochondrial membrane, in agreement with the typical profile of mitochondrial 
potassium channel activators [151]. At the best of our knowledge, mitoIKCa channels have not 
been presently recognized in the heart. 
 
C.3 MitoSKCa channels 
Very recently, a small conductance calcium-sensitive potassium (SKCa, or KCa2) channel has 
been identified and localized thanks to immune-electron microscopy and purified by 
isoelectric focusing on the inner membrane of guinea-pig cardiac mitochondria and in 
mitochondria of neuronal cells [152]. The authors furnished convincing evidence of the 
presence of mitoSKCa channels, and also demonstrated that their activation triggers the Ph-
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PreC and then confers cardioprotection, as shown by metabolic and functional improvement 
recorded during the reperfusion on isolated and perfused guinea-pig hearts. Finally, the 
activation of mitoSKCa channels appears to converge, similarly to mitoBKCa and mitoKATP 
channel opening, on the control of intra-mitochondrial ROS generation [80, 125, 133]. 
Within the compounds tested as activators of mitoSKCa, DCEBIO was shown to induce 
cardioprotection which was antagonized by both NS8593 [153] an antagonist of SKCa 
isoforms and TBAP, a scavenger of peroxynitrite (SOD mimetic), thus indicating that the 
mitoSKCa channel opening is mediated by SOD [80] (in figure 4 is shown the SKCa activator). 
 
D MitoKv channels 
 
In 2005, Szabò and colleagues found the presence of voltage-gated 1.3 potassium (Kv1.3) 
channels on the inner membrane of mitochondria in T lymphocytes [154]. Later, Kv1.3 
channels were also reported in the mitochondria of macrophages [155] and hippocampal 
neurons [156]. 
Although the Kv1.3 channels described in mitochondria of hippocampal neurons displayed a 
different conductance with respect to the Kv1.3 channels on lymphocytes, both channels are 
sensible to margatoxin. Interestingly, a hyperpolarization of mitochondrial membrane 
potential could be recorded upon inhibition of mitoKv1.3, indicating that in energized 
mitochondria these channels are normally active [154], and their inactivation is important in 
the initiation of apoptosis [157]. 
The Zoratti/Szabò group further reported that J774 macrophages express Kv1.3 and Kv1.5 
channels in their mitochondria and that inhibition of both channels with specific blockers 
could efficiently induce apoptosis in this macrophage cell line. Thus, these results indicate 
that the mechanism proposed for Kv1.3 can be extended to other Kv channels in 
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macrophages, important players in the immune system [158-159]. Noteworthy, Leanza et al. 
have recently shown that the inhibition of mitoKv1.3 induces a drastic effect on tumor cell 
apoptosis by means a Bax/Bak-independent pathway [160-161].  
At the best of our knowledge, mitoIKCa channels have not been presently recognized in the 
heart. 
 
 
E MitoTASK-3 channels 
 
Recently, TASK-3 (KCNK9), one of the twin-pore domain potassium channels, was 
described in mitochondria of melanoma, keratocyte cells [162] and embryonic rat 
hippocampus [163], while its functional properties remain to be largely investigated [164]. In 
2014, the Szewczyk group demonstrated that this channel has a protective role in human 
keratinocytes after UVB radiation exposure [165]. At the best of our knowledge, mitoTASK-3 
channels have not been presently recognized in the heart. 
 
 
F “Dirty” drugs able to activate mitoKATP and mitoBKCa channels. 
Levosimendan, a cardiovascular drug used to treat acute and decompensated heart failure, 
owes its action to a calcium sensitization of the contractile proteins and to a vasorelaxing 
effect mediated by the opening of sarcolemmal KATP channels [166-167]. Recently, 
levosimendan has been observed to activate also the mitoKATP channels [168-169] and has 
been demonstrated to protect myocardium against the I/R injury [170]. 
Moreover, it has been speculated that the cardioprotective effects of numerous polyphenols 
(such as theaflavin and epigallocatechin) are due to an activation of mitoKATP channels [171]. 
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Volatile anesthetics activate some of the same pathways that lead to protection through IPreC 
or IPostC. Zaugg et al. verified that exposing cardiomyocytes to the volatile anesthetics, 
sevoflurane and isoflurane, before myocardial ischemia, the damage decreased in a dose-
dependent manner [172]. These effects were antagonized by the mitoKATP channel blocker 5-
HD, demonstrating that they prime the mitoKATP channels [173-175].  
In addition, Stumpner at al. reported the involvement of the BKCa channel in the desflurane-
induced post-conditioning in mice subjected to a coronary artery occlusion [176]. 
Other molecules, not described as BKCa openers, belonging to different therapeutic class, such 
as phosphodiesterase inhibitors (cilostazol and sildenafil), can mimic the Ph-PreC by an 
activation of mitoBKCa [177, 146]. 
Very recently it has been demonstrated that naringenin, a flavanone abundant in the Citrus 
genus, possesses cardioprotective activity by opening the mitoBKCa channels. Indeed, 
naringenin treatment  before the onset of in vivo acute infarct or a global ischemia halved I/R 
injury sizes. Moreover, on isolated cardiac mitochondria, naringenin was able to produce all 
the typical effects of the mitoK channel openings, and the involvement of mitoBKCa was 
suggested by the inhibitory effect of selective blockers [178]. Similarly, Gao et al., published 
a work on the cardioprotective effect of the isoflavone puerarin. They observed the 
involvement of mitoBKCa channels, since the pretreatment with paxilline prevented its 
beneficial effect [179] (in figure 5 are shown the chemical structures of the dirty drugs). 
 
 
G Innovative mito-delivered drugs 
Ideal mitoK channel openers should have the ability to easily penetrate into the cell and be 
effectively delivered to their mitochondrial target. The lack of this pharmacokinetic property 
is a serious limitation for the clinical application of mitoK channel openers. Therefore a 
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timely and challenging issue is to obtain anti-ischemic drugs highly selective for the mitoK 
channels and able to be selectively delivered into mitochondria (in figure 6 are shown the 
chemical structures of the mito-delivered drugs). For this purpose, the most widely used 
synthetic strategy is the combination in a single molecule of the pharmacophore moiety and a 
“mitochondria-addressed” cation, such as tetraphenyl phosphonium (TPP+), throughout an 
appropriate aliphatic linker. Generally, the length of the spacer  influences the degree of 
hydrophobicity of such mitochondriotropic agents and consequently it could affect their 
efficacy both in in vitro and in vivo models [180-181]. These compounds are able to rapidly 
and extensively accumulate into mitochondria, driven by the mitochondrial membrane 
potential (about -180 mV)[182-183]. The main advantages in the use of lipophilic cations are 
their low reactivity and poor interaction with cell components. From a medicinal chemistry 
point of view, an example of synthetic pathway to obtain mitochondriotropic compounds is 
depicted in figure 7. In this instance, in order to deliver resveratrol into mitochondria, this 
polyphenol has been combined with  TPP+ [184] (Figure 7A). In particular, resveratrol has 
been submitted to an O-alkylation by the use of an appropriate bis-halide-alkyl chain and then 
converted to the desired TPP+ derivative by means of two consecutive nucleophilic 
substitution steps: Cl- → I- →TPP+I-. A most recent paper [185] reports the synthesis and the 
pharmacological profile of SkBQ (10-(p-benzoquinonyl)decyltriphenylphosphonium 
bromide). As regards the synthetic pathway, also in this case the p-benzoquinone was 
alkylated  with the appropriate alkylcarboxylic acid by the use of a radical substitution 
reaction with simultaneous decarboxylation catalyzed by silver nitrate in the presence of 
ammonium persulfate. The product was then converted to the desired TPP+ derivative by 
means of a nucleofilic substitution ( Br- → TPP+I-) (figure 7B). The above examples of 
synthetic pathways can be usefully applied to a plethora of different compounds in order to 
target them to mitochondrion. Many TPP+-based antioxidants have been tested for their 
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selectivity to mitochondria, including MitoVitE, MitoQ and MitoL. To date, a TPP+ derivative 
of MitoQ, an ubiquinol antioxidant, has received great attention, since it is endowed with 
cardioprotective effects in the I/R injury model [186-188]. In a recent study Mito-Tempol (a 
piperidine nitroxide conjugated to the TPP+) exhibited cardioprotective effects in an in vivo 
rat model [189].  
Besides the lipophilic cations, some peptides can also be used to direct molecules to 
mitochondria. Particularly the Szeto-Schiller (SS) peptides are able to selectively bind to the 
inner membrane, independently of potential. This feature is an advantage, because they can 
penetrate even into the diseased organelles with reduced potential [190]. An important 
difference between lipophilic cations and the SS-peptides is that the latter have an intrinsic 
activity on mitochondria. In particular, SS-02 and SS-31 were able to scavenge hydrogen 
peroxide, hydroxyl radical, and peroxynitrite in vitro [191] and the observed decrease of 
myocardial I/R injury in ex vivo and in vivo studies was attributed to their ability to promote 
mitochondrial respiration and ATP synthesis, reduce ROS generation, and inhibit 
mitochondrial swelling [192] 
Noteworthy, new penetrating cations have been very recently developed. They are rhodamine-
19, berberine and palmatine conjugated through aliphatic linkers with plastoquinone (SKQR1, 
SKQBerb, SKQPalm, respectively), endowed with antioxidant effects; they have been shown 
to penetrate into mitochondrial matrix, both in isolated mitochondria and in living cells in 
culture [193]. 
 
 
4- LOSS OF EFFICACY OF MITOCHONDRIAL POTASSIUM CHANNEL 
ACTIVATORS IN AGEING 
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Presently, the number of people over the age of 65 is growing, especially in western society. 
The incidence and the prevalence of cardiovascular diseases, such as coronary artery disease, 
hypertension and acute myocardial infarct, increases proportionally with age. At the same 
time the IPreC and IPostC self-defence mechanisms reduce their efficacy and the 
vulnerability of myocardium increases with ageing [194].Therefore an amplification of the 
damage is observed when aged hearts are exposed to various kinds of stress. The loss of 
intrinsic myocardial tolerance to ischemia in mouse myocardium begins during middle-age 
(12 months) and becomes more evident with ageing (18 months and 24-28 months). Similar 
results have been observed in rats (6 vs 24 months) [195-198]. The fundamental processes 
that lead to cardiac ageing and loss of myocardial resistance are not yet understood, although 
several mitochondrial defects have been detected, including a reduced activation of STAT3 
observed in old mice [199] or an impaired connexin 43 translocation in the mitochondria of 
aged heart, that may contribute to the loss of efficacy of cardioprotective strategies [200] It is 
thought that the mitochondrial dysfunction in electron transport or oxidative phosphorylation, 
typical of ageing, is closely implicated in the increased susceptibility to ischemic injury. 
These age-related mitochondrial defects are reflected by partial depolarization of membrane 
potential and greater probability of MPTP opening [11, 201].  
In this respect, the mitoKATP channel activation, that is generally considered an effector in the 
protection pathway, can lead to ineffective cardioprotection in ageing hearts [202]. Several 
observations suggested that cardioprotective signaling pathways, acting through mitoKATP 
channels, are compromised with ageing; although it is unclear whether the attenuated cardiac 
mitoKATP channel function is due to changes in channel density, responsiveness to stress 
stimuli or a defective respiratory chain [203-204]. Similar data have been also obtained when 
mitoBKCa channel openers were used on aged hearts. In aged rat heart mitochondria, Heinen 
and his colleagues have observed that the opening of mitoBKCa channels by NS1619 was 
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ineffective on respiratory parameters and then was unable to influence the respiratory 
efficacy, suggesting the possibility of a decreased sensitivity of mitoBKCa channels due to 
ageing [205].  
This result is ageing-dependent [206-207], but also gender-dependent. In fact, the infarct-
limiting efficacy of diazoxide is less evident in aged male hearts, and entirely absent in aged 
female hearts, suggesting a more severe defective function of mitoKATP channels in aged 
female hearts [208]. Such evidence leads to hypothesize the implication of estrogens in the 
ageing; in fact, these hormons may stimulate directly (acting on specific receptors localized in 
the organelle) and indirectly (regulating the mitochondrial transcription) the mitochondrial 
function [209]. Moreover, a recent paper highlighted an altered expression of six proteins in 
cardiac mitochondria of aged female rats [210]. 
Since human life expectancy increases due to effective treatment of cardiovascular and other 
diseases, there is a stringent need for the development of strategies designed to preserve the 
efficiency of cardioprotective mechanisms also in aged hearts or to slow ageing.  
Although numerous drugs produce Ph-PreC in experimental models, none has been translated 
to clinical use, with the consequence that currently there is no FDA approved drug for 
reducing I/R-induced myocardial injury [211]. 
Clearly, the blockage or the reversal of the dysfunction of mitochondrial ion channels may 
improve  the function of the organelle, and may also be beneficial in slowing down the 
process of mitochondria ageing, and the related pathologies . 
 
5  CONCLUSIONS 
Mitochondria play a unique and crucial role in the cardiac protection against I/R injury, then 
emerging therapeutic approaches are focused on the development of new molecules acting on 
specific mitochondrial sites. In this respect, the modulation of the flow of different ion species 
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across the mitochondrial membrane is considered as a greatly promising pharmacological 
approach. Since the accumulation of Ca++ into the matrix is a crucial step, in the dramatic 
chain of events leading to I/R-induced cell death, new intriguing strategies are addressed at 
reducing Ca++ accumulation by direct pharmacological inhibition of the Ca++ uniporter and of 
the MPTP [212-215]. Together with these newest pharmacological targets, mitochondrial 
potassium channels represent a reliable and well tried field of research. Indeed, extensive 
research has been performed in the last years, in order to highlight the exact role of these 
mitochondrial ion channels and innovative drugs have been developed in order to mimic 
conditioning phenomena. Nevertheless, to date, there are still many dark sides: 1) the exact 
molecular composition of many mitochondrial channels remains elusive; 2) the mitochondrial 
pathways triggered by the activation of these channels have not been clearly understood 
[216]; 3) possible changes in expression/activity of mitochondrial potassium channel in 
elderly patients should be better clarified;  4) similarity between sarcolemmal and 
mitochondrial potassium channels may compromise the development of  selective drugs. 
Many difficulties can be correlated, at least in part, with the internal localization of these 
channels, hardly accessible with the usual experimental techniques, and data should be 
carefully interpreted.  
Below we have inserted an appendix in which we attempted to describe the most used 
experimental approaches aimed at studying mitochondrial potassium channels and their 
physio-pathological roles, on intact cell or in isolated organelles. 
 
 6- APPENDIX  
Techniques used to characterize mitochondrial potassium channels 
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Approaches on isolated mitochondria are better for mechanistic studies, in order to highlight a 
specific mitochondrial target. The investigation is clearer, lacking the interference with 
cytosolic factors; however, sound protocols of isolation have to be carry out, in order to avoid 
damage of mitochondria [217], since they may be unavoidably aggregated or damaged by 
unreliable procedures.  
Conversely, working on intact cells, shows the advantage to leave the organelles in their 
cellular environment, where the interactions with the cell are preserved, then obtaining results 
with a greater physiological relevance, without artifacts due to mitochondria isolation [218]. 
Nevertheless, the results can be more complex and difficult to understand, mostly if a 
mitochondrial channel has to be investigated.  
However, the main obstacle in studying the mitoK channels is the availability of reliable 
assays. As above described, the opening of a mitoK channel is responsible for 
cardioprotection through a mild depolarization and consequent reduction of Ca++-uptake and 
increase of Ca++-release, thus reducing the probability of MPTP opening and apoptotic death. 
Therefore the possible strategies of study are two: to directly record the potassium 
movements, or to evaluate the mitochondrial downstream events consequent to the K+ 
movements.  
 
A Direct measurements of potassium ions movements 
In order to achieve a direct measurement of the mitoK current the work on isolated 
mitochondria is fundamental, since undesired recording of sarcolemmal K+ currents cannot be 
excluded in intact cells. An important contribution to understand the pharmacological 
properties of the mitoK channels comes from the use of electrophysiological techniques, 
where mitochondria are patched by micro-electrode and the current of the single potassium 
channel can be recorded. For this purpose, two methods can be used: voltage-clamp on planar 
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lipid bilayer and patch-clamp on mitochondria or mitoplasts [219]. The first one is based on 
the incorporation of purified inner or outer mitochondrial membrane fragments, containing 
the mitochondrial channel of interest, with liposome to form bilayer vesicles. This method 
allows the study of channels, which are not easily accessible for the patch-clamp technique 
[220]. 
On the other hand, the patch-clamp method on intact mitochondria has the advantage of 
holding the channels in their natural environment, because the isolation process for the bilayer 
method may be harmful for the channel. Disadvantages of the patch-clamp technique are: a) 
mitochondria are in close contact with membranes of the endoplasmic reticulum and it might 
be difficult to completely remove these membranes [221]; b) some channels might not be 
accessible for the glass pipette; thus, the patch clamp technique might fail to detect some 
important ion channel currents [222]. 
Even mitoplasts, prepared from the mitochondrial fraction by a swelling procedure or with 
French press technique [223] have been successfully employed for electrophysiological 
measurements of K+ channel currents. In particular, Inoue et al., used this technique to 
demonstrate for the first time the activity of mitoKATP channels [76]. 
The major advantage of this technique is the possibility to work only with the K+ channel of 
the inner membrane; in fact it is well known that most preparations of isolated mitochondria 
can be contaminated with plasma membranes, unless further purified by density gradient 
centrifugation and even then it is difficult to achieve complete removal of contaminating 
membranes [224]. 
In isolated mitochondria, potassium movements can be also directly measured using K+-
sensitive mini-electrodes or fluorescent indicators.  
K+-sensitive mini-electrodes are available, however they are not satisfactorily sensitive and 
reliable [225]. Instead, potassium binding fluorescence indicators are more sensitive and 
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allow the recording of changes of potassium ions in the mitochondrial matrix, as reported by 
Costa et al., 2006 [80, 133, 226].  
Alternatively, fluorescent probes sensitive to thallium (Tl+), a potassium-mimetic cation, are 
either commercially available or can be easily homemade. The ionic radii of Tl+ and K+ are 
similar, and thus heavy metal is widely and originally used to study sarcolemmal trans-
membrane K+ flow. Such an experimental approach has been recently applied to evaluate 
mitoK currents and published by Wojtovich and his colleagues, and used also by us [113, 
178].  
 
B Indirect measurements of potassium ions movements 
Most studies on the mitoK channels to date use indirect approaches on isolated mitochondria 
or on intact cells, by measuring downstream effects the mitochondrial K+ uptake, such as 
changes in respiration, matrix alkalinization, flavoprotein fluorescence, and swelling-induced 
light scatter [227]. Nevertheless, the reliability of these methods is limited by the ability of 
other mitochondrial phenomena (e.g, electron transport chain activity, volume changes, 
membrane potential) to interfere with the measured parameters.  
As regards flavoproteins, they are able to emit autofluorescence in the oxidated, but not 
reduced state [228], hence this can reflect the electronic trafficking of mitochondria and can 
be used to monitor the metabolic state of cells. Indeed, the autofluorescence of flavoproteins 
in intact cardiac myocytes is used as an indirect indicator of mitochondrial K+ channel 
activity. Marban and colleagues reported that diazoxide caused an oxidation of mitochondrial 
flavoproteins, reversed by 5-HD. Similar effects have been reported in guinea-pig myocytes 
using NS1619. However, this experimental approach has many limitations, and other 
researchers have failed to reproduce these results, speculating that non-specific actions of 
diazoxide or NS1619 could influence the assay [229-230]. In the case of diazoxide, the 
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increase in flavoprotein fluorescence can be attributed to the inhibition of succinate 
dehydrogenase, protonophoric uncoupling, or even transient opening of the MPTP.  
The swelling assay is based on the fact that the K+ uptake into isolated mitochondria is 
followed by osmotically-obliged water, leading to mild swelling, thus the ion movements lead 
to changes in matrix volume, that can be measured at a wavelength of 520 nm. In particular, 
the swelling causes a decrease of refractive index. This assay has been criticized as 
irreproducible by some laboratories, because the mitochondrial isolation timing appears to be 
a critical factor. 
Another approach used to investigate the activity of mitoK channels either in cardiac 
myocytes and in isolated mitochondria, is based on the recording of the depolarization of the 
mitochondrial membrane potential. Lipophilic cationic compounds are often used for the 
determination of ΔΨ, in fact these compounds permeate the mitochondrial membranes and 
distribute in accordance with the Nernst equation; thus the accumulation in the mitochondrial 
membrane matrix is driven by ΔΨ. 
These lipophilic ions include fluorescent, radiolabeled and unlabeled probes.  
As regards the unlabeled probes, they can be determined by ion-selective electrodes, that 
allow the continuous monitoring of changes in mitochondrial membrane potential. The 
lipophilic cation most used is the tetraphenylphosphonium (TPP+), with its selective electrode 
[95, 178, 231, 232]. 
Direct measurements of membrane potential can be also carried out with fluorescent probes, 
monochromatic lipophilic cations, such as dihexyloxacarbocyanine (DiOC6(3)) and 
rhodamines, or JC-1 (5,5',6,6'-tetrachloro1,1',3,3'-tetramethylbenzimidazolylcarbocyanine 
iodide), whose emission spectrum shifts from red, when it forms into mitochondria J-
aggregations, to a green emission reflecting the monomeric form of JC-1, due to the exit from 
mitochondria after membrane depolarization. The ratio of this green/red fluorescence is 
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independent of mitochondrial shape, density, or size, but is influenced only by the membrane 
potential. Fluorescence probes are largely used on intact cells, because if it has at its disposal 
isolated mitochondria, easier techniques are available. The choice of the probe is related 
largely to their equilibration characteristics and also to their toxicity versus the electron 
transport chain.  
A net K+ uptake results necessarily in matrix alkalinization, because overall transport must be 
electroneutral, then the K+ influx will be balanced exactly by the electrogenic H+ efflux driven 
by the electron transport. In other words, the K+ for H+ exchange would increase matrix pH 
by an amount determined by the buffering power of the matrix. Costa et al. [233] reported that 
the increase in matrix K+, mediated either by mitoKATP or by potassium ionophor 
valinomycin, was accompanied by matrix alkalinization. This effect accounts for the role of 
mitoKATP in cardioprotection and can be measured by means of pH-sensitive fluorescence 
probes (such as 2',7'-biscarboxyethyl-5(6)-carboxyfluorescein) [133, 234].  
Finally, the mitoK opening influences calcium movements across the mitochondrial 
membrane. Changes of Ca++ movements can be recorded by means of specific calcium-
sensitive mini-electrodes. Using this approach, Holmuhamedov and colleagues observed that 
diazoxide and pinacidil reduced mitochondrial Ca++uptake, in agreement with the evidence 
that the Ca++-accumulation through the Ca++ uniporter is driven by the difference in 
membrane potential across the inner mitochondrial membrane. Conversely, this approach 
allowed to demonstrate also that mitoK channel openers can promote Ca++ discharge from 
Ca++ pre-loaded mitochondria, phenomenon at the basis of cardiac protection [226, 235]. 
The primary mitochondrial Ca++ release pathway includes the MPTP, which can be activated 
by mitochondrial membrane depolarization and swelling [236-238]. Activation of mitoKATP 
channels has been associated with mitochondrial membrane depolarization and can prime 
 30 
 
swelling [107, 231], transiently activating the MPTP, and thus causing Ca++ discharge from 
preloaded mitochondria. 
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9- LEGENDS 
 
Figure 1 
A) Schematic representation of events occurring during ischemic period. 
The Na+/K+ ATPase is inhibited (1) because of the decline of ATP concentrations, leading to 
Na+ accumulation and membrane depolarization, which triggers the opening of voltage gated 
Ca++ channels (2). Because of the high cytosol concentration of Na+, the Na+/Ca++ antiporter, 
that usually pumps Ca++ out of the cell and Na+ into the cell, is inhibited or reversed, leading 
to further overload of Ca++ (3). The mitochondrial matrix massively accumulates Ca++ (4). 
During ischemia, the rate of glycolysis rises causing a metabolic production of lactic acid. 
The high intracellular concentration of  Na+ inhibits the Na+/H+ antiporter (5), with 
consequent lowering of the cytosol pH. Although the Ca++ accumulation in the matrix would 
be a triggering stimulus for MPTP opening, the acidic pH inhibits the activation of MPTP (6). 
B) Schematic representation of events occurring duringreperfusion. 
During reperfusion, the reactivation of aerobic metabolism restores the levels of ATP. The 
Na+/K+ ATPase activity is restored (1), leading to the normalization of the cytosol 
concentration of electrolytes (2) and H+ (3). In conditions of physiological pH, the high levels 
of matrix Ca++ triggers the opening of MPTP (4), with consequent activation of pro-apoptotic 
pathways. 
Figure 2  
Schematic representation of I/R event, IPreC, IPostC and PhPreC protocols. 
Figure 3 
Schematic description of one of the different mechanisms which links the activation of mitoK 
channels to the control of mitochondrial calcium movements and modulation of the MPTP. 
The activation of mitoK channels causes inward flow of potassium ions, weak membrane 
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depolarization and reduced driving force for calcium accumulation in the matrix, limiting the 
formation of MPTP and its opening. This mechanism can, at least in part, reduce the release 
of mitochondrial pro-apoptotic factors during reperfusion and thus preserve mitochondrial 
membrane integrity. 
Figure 4 
Chemical structures of non-selective KATP channel openers (cromakalim, diazoxide and 
pinacidil), selective mito-KATP activators (BMS derivatives, F163, and KR-31466), BKCa 
openers (NS1619, CGS7184, NS11021) and SK activator (DCEBIO). 
Figure 5 
Chemical structures of “Dirty” drugs able to activate mitoKATP and mitoBKCa channels. 
Figure 6 
Chemical structures of mito-targeted drugs: (A) TPP+-based conjugate drugs (B) peptide-
based conjugate drugs (c)plastoquinone-based conjugate drugs. 
Figure 7 
Reliable synthetic strategy to obtain mitochondriotropic compounds, for the delivery of 
resveratrol (A) or SkBQ (B) into mitochondria. 
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